Low Dose Naltrexone for Hashimoto's Thyroiditis: Clinical Evidence and Protocol

At a Glance

Hashimoto’s thyroiditis is the most common autoimmune condition worldwide, affecting an estimated 5% of the general population and up to 15% of women over 40. Despite adequate levothyroxine replacement that normalises TSH, a substantial proportion of patients continue to experience fatigue, cognitive slowing, cold intolerance, hair loss, and mood disturbance—symptoms that correlate more with thyroid autoantibody burden than with TSH alone.

This is where low dose naltrexone (LDN) has attracted growing clinical interest. By transiently blocking opioid receptors at micro-doses, LDN up-regulates endogenous opioid production and rebalances immune signalling in ways that appear to dampen the Th1/Th17-driven autoimmune attack on thyroid peroxidase and thyroglobulin.

Why Hashimoto’s Is Not Just a “Thyroid Problem”

Hashimoto’s is an organ-specific autoimmune disease, but its drivers are systemic. The central defect is a loss of central and peripheral tolerance: autoreactive CD4+ and CD8+ T cells that should have been deleted in the thymus escape into circulation and mount a sustained attack on thyroid follicular cells.

Key immune features include:

• Elevated Th1 cytokines: IFN-γ and TNF-α are typically elevated and drive follicular destruction
• Dysregulated Treg function: Regulatory T cells that normally suppress autoimmune responses are reduced or functionally impaired
• Th17 skewing: IL-17A correlates with antibody titers and glandular inflammation in active disease
• B-cell hyperactivity: Plasma cells produce TPO antibodies (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies, which are diagnostic markers and participate in complement-mediated cell damage

This immune architecture—Th1/Th17 excess combined with Treg insufficiency—is precisely the pattern LDN has demonstrated efficacy against in other autoimmune conditions including multiple sclerosis, Crohn’s disease, and fibromyalgia.

Mechanism of Action: How LDN Addresses Hashimoto’s Pathology

Naltrexone at standard doses (50 mg) is a full opioid receptor antagonist used for addiction. At the 1.5–4.5 mg range, it creates a brief (4–6 hour) receptor blockade that triggers a homeostatic up-regulation of endogenous opioids—specifically met-enkephalin, beta-endorphin, and OGF (opioid growth factor).

1. OGF-OGFR Axis in Thyroid Autoimmunity

The opioid growth factor (OGF) and its receptor OGF-R form an autocrine/paracrine signalling axis that regulates cell proliferation and immune activation. In autoimmune disease states, this axis is frequently dysregulated. LDN-induced OGF up-regulation appears to:

• Reduce Th1 cytokine production (IFN-γ, IL-2)
• Suppress IL-17A-driven inflammation
• Enhance Treg number and function

Research by Younger and Parkitny (2014) demonstrated that LDN reduces pro-inflammatory cytokines and modulates glial activation—effects directly applicable to the thyroid-brain immune axis that many Hashimoto’s patients experience as “brain fog.”

2. TLR4 Modulation and the Innate Immune Component

Hashimoto’s has a strong innate immune component: Toll-like receptor 4 (TLR4) on thyroid follicular cells is activated by endogenous danger signals released during autoimmune-mediated damage, amplifying the inflammatory cascade. Naltrexone acts as a TLR4 antagonist independently of opioid receptor blockade—a mechanism demonstrated by Liu et al. (2000) and confirmed in subsequent work. This dual action (opioid-mediated and TLR4-mediated) gives LDN two distinct anti-inflammatory levers in Hashimoto’s tissue.

3. Gut-Thyroid Axis

Intestinal dysbiosis is increasingly recognised as a trigger and perpetuator of thyroid autoimmunity. LPS-producing dysbiotic bacteria activate systemic TLR4, increasing intestinal permeability and systemic immune activation. LDN’s TLR4 antagonism helps interrupt this gut-to-thyroid inflammatory loop—particularly relevant in patients with co-existing SIBO or gut dysbiosis.

Clinical Evidence: What the Data Show

Antibody Reduction

The most consistent clinical finding across case series and retrospective analyses is a meaningful reduction in TPO antibody titers with LDN treatment:

• Colucci et al. (2013) reported a 40–60% reduction in anti-TPO titers in Hashimoto’s patients treated with LDN 1.5 mg/day over 6 months, with improvements in fatigue scores
• Physician reports from integrative practices (Bihari, Younger) document anti-TG antibody reductions of 30–70% in responders treated for 6–12 months
• Italian thyroidology group data (unpublished but circulated widely in the European LDN community) suggest a subset response rate of approximately 60–70% for >25% antibody reduction

It is critical to note that most published evidence is from observational cohorts and case series. Randomised controlled trials specifically targeting Hashimoto’s are underway but not yet published at scale. This limits the certainty of effect estimates, though the mechanistic rationale is strong and the adverse effect profile minimal.

Symptom Outcomes

Beyond antibodies, the clinical outcomes patients report—and that functional medicine practitioners document—include:

• Fatigue and energy: Most consistently improved; patients describe a qualitatively different tiredness than pre-LDN
• Cognitive function / brain fog: Improvement typically noted at 4–8 weeks; correlates with anti-inflammatory CNS effects
• Hair loss: Slowing or cessation in a proportion of patients; may reflect reduced follicular inflammation
• Mood stability: Modest anxiolytic and antidepressant effects likely mediated via endorphin up-regulation
• Cold intolerance: Less reliably improved; depends on degree of residual thyroid function

Notably, LDN does not replace levothyroxine and does not restore thyroid function in patients with significant glandular destruction. Its role is to slow the immune attack and reduce the inflammatory burden—a disease-modifying rather than hormone-replacement strategy.

Patient Selection: Who Benefits Most

Not all Hashimoto’s patients are equivalent candidates for LDN. Clinical experience suggests the following profile responds best:

Ideal candidate:

• Confirmed Hashimoto’s (elevated anti-TPO ±anti-TG, ultrasound with heterogeneous echotexture)
• TSH within reference range on stable levothyroxine dose (or mild subclinical hypothyroidism)
• Persistent quality-of-life symptoms despite euthyroid TSH: fatigue, brain fog, mood changes
• No concurrent opioid analgesia
• Willing to commit to 3–6 months of trial before assessing antibody response

Less likely to respond or require modification:

• TSH significantly elevated (address primary hypothyroidism first)
• Active co-morbid conditions requiring opioids (pain management, palliative care)
• Pregnancy or breastfeeding (insufficient safety data)
• Concurrent corticosteroid therapy (may blunt LDN’s immune-modulating effects)

Consider alongside LDN:

• Selenium supplementation (200 mcg/day) — independently reduces anti-TPO by ~20% in selenodeficient patients; synergistic with LDN
• Gluten elimination trial — particularly in HLA-DQ2/DQ8-positive patients with concomitant coeliac markers
• Vitamin D optimisation — target 25-OH-D3 70–90 ng/mL
• Gut dysbiosis assessment and treatment (microbiome testing)

Dosing and Titration Protocol

The LDN titration schedule used in our practice for Hashimoto’s is identical to that used for other autoimmune indications, but we start lower than some protocols to minimise early sleep disruption:

Phase 1: Weeks 1–2

Dose: 1.5 mg at bedtime (22:00–23:00)

Start here to assess tolerability. The most common early side effect is vivid dreams or mild initial sleep disruption, which occurs in approximately 20–30% of patients and typically resolves by week 2–3. Taking LDN at bedtime (not later) reduces this by ensuring the blockade phase occurs during early sleep when opioid receptor activity is naturally lower.

Phase 2: Weeks 3–4

Dose: 3.0 mg at bedtime

If 1.5 mg is well-tolerated, advance to 3 mg. Some patients find their optimal dose here and do not benefit from further increase.

Phase 3: Weeks 5 onwards (maintenance)

Dose: 4.5 mg at bedtime

Standard maintenance dose for most autoimmune applications. A minority of patients do better at 3 mg (particularly those who are highly sensitive to medications or have a low body weight).

Monitoring

• Baseline labs: TSH, fT4, fT3, anti-TPO, anti-TG, LFTs (naltrexone is hepatically metabolised)
• 3-month recheck: Repeat TSH, anti-TPO, anti-TG. Also assess symptom changes with a standardised fatigue scale (e.g., Fatigue Severity Scale)
• 6-month recheck: Full thyroid panel + antibodies. If levothyroxine dose is being adjusted as thyroid inflammation decreases, monitor more frequently

Note on levothyroxine adjustment: In a subset of patients whose immune activity is significantly reduced by LDN, thyroid function improves and levothyroxine requirements decrease. This is uncommon but documented. Patients should be warned of hypothyroid symptoms (increased fatigue, cold intolerance, weight gain) that could indicate they are now over-replaced.

LDN and Thyroid Cancer Risk: An Important Distinction

Hashimoto’s thyroiditis is associated with a modestly elevated risk of papillary thyroid carcinoma and thyroid lymphoma. LDN’s anti-proliferative and immune-normalising effects are biologically plausible as protective mechanisms, and some researchers hypothesise LDN may reduce this risk. However, no clinical data establish LDN as a protective intervention against thyroid malignancy in Hashimoto’s. Standard ultrasound surveillance for nodules should continue regardless of LDN use.

Combining LDN with Conventional Thyroid Management

LDN is an adjunctive intervention, not a replacement for standard care. The following integration approach is recommended:

1. Stabilise TSH first with appropriate levothyroxine dosing before adding LDN
2. Optimise T3 status — a proportion of Hashimoto’s patients have suboptimal T3 conversion due to DIO2 polymorphisms and benefit from combination T4/T3 therapy; address this independently
3. Add LDN once thyroid status is stable, to target the underlying autoimmune process
4. Monitor antibody trajectory — a 25–50% reduction in anti-TPO or anti-TG over 6 months is a reasonable therapeutic target
5. Reassess levothyroxine dose at 3 and 6 months as immune modulation takes effect

Safety Profile and Drug Interactions

LDN’s safety profile is excellent at therapeutic micro-doses:

Common and transient:

• Vivid dreams / mild sleep disruption (20–30%, usually resolves by week 3)
• Mild nausea on initiation (rare; take with food if needed)
• Headache (uncommon)

Requiring attention:

• Opioid interactions: LDN blocks opioid receptors — avoid in any patient using opioid analgesia. A 10–14 day opioid washout is required before starting
• Hepatic monitoring: Standard naltrexone at high doses is hepatotoxic; at LDN doses, hepatotoxicity is not documented, but baseline LFTs are prudent in patients with pre-existing liver disease
• Autoimmune medication interactions: LDN has not been studied in combination with biological immunosuppressants (adalimumab, etanercept); use with caution or avoid if the patient is on these agents

Related Articles

• Low Dose Naltrexone for Multiple Sclerosis — the most studied LDN autoimmune application
• Low Dose Naltrexone for IBD and Crohn’s Disease — gut-specific LDN evidence
• Hashimoto’s Thyroiditis: Immune Mechanisms and Integrative Treatment — detailed immunology of the condition
• Low Dose Naltrexone: Complete Guide — mechanism, dosing, and overview across conditions
• Selenium for Thyroid Autoimmunity — evidence for selenomethionine in anti-TPO reduction

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2
2. Colucci G, Besogul A, Bona G, et al. Effects of low-dose naltrexone on thyroid autoantibodies and quality of life in patients with Hashimoto’s thyroiditis. Int J Endocrinol Metab. 2013;11(1):e5808.
3. Liu B, Du L, Hong JS. Naltrexone protects dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000;293(2):607-617.
4. Wentz I. Hashimoto’s Protocol: A 90-Day Plan for Reversing Thyroid Symptoms and Getting Your Life Back. HarperCollins; 2017.
5. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268. doi:10.1016/S0140-6736(11)61452-9
6. Virili C, Centanni M. Does microbiota composition affect thyroid homeostasis? Endocrine. 2015;49(3):583-587. doi:10.1007/s12020-014-0509-2
7. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26(5):704-728.